CAMP4 Therapeutics has formed a research collaboration with Alnylam Pharmaceuticals focused on identifying new druggable targets to address an undisclosed rare disease of the liver. The collaboration brings together CAMP4’s expertise in pinpointing signaling targets that control the expression of genes with Alnylam’s expertise in RNAi therapeutics development to advance novel rare disease drug candidates.   “We are excited to partner with Alnylam given its leadership in the RNAi and liver dise...